The
IGF-I pathway and
renin-
angiotensin-
aldosterone axis are both involved in the pathogenesis of
hypertension and
atherosclerosis, but no information is available about
IGF-I and
aldosterone interaction or their potential synergistic effects in vascular smooth muscle cells (VSMCs). The aims of this study were to investigate whether
aldosterone influences
IGF-I signaling and to determine the mechanism(s) by which
aldosterone affects
IGF-I function.
Aldosterone resulted in significant increases in the Akt (1.87 ± 0.24, P < 0.001), MAPK (1.78 ± 0.13, P < 0.001), p70S6kinase (1.92 ± 0.15, P < 0.001),
IGF-I receptor (1.69 ± 0.05, P < 0.01), and
insulin receptor substrate-1 (1.7 ± 0.04, P < 0.01) (fold increase, mean ± SEM, n = 3) phosphorylation responses to
IGF-I compared with
IGF-I treatment alone. There were also significant increases in VSMC proliferation, migration, and
protein synthesis (1.63 ± 0.03-, 1.56 ± 0.08-, and 1.51 ± 0.04-fold increases compared with
IGF-I alone, respectively, n = 3, P < 0.001).
Aldosterone induced
osteopontin (OPN)
mRNA expression and activation of αVβ3-integrin as well as an increase in the synthesis of
IGF-I receptor. The enhancing effects of
aldosterone were inhibited by
eplerenone (10 μmol/liter),
actinomycin-D (20 nmol/liter), and an anti-αVβ3-integrin antibody that blocks OPN binding. The
antioxidant N-acetylcysteine (2 mmol/liter) completely inhibited the ability of
aldosterone to induce any of these changes. In conclusion, our results show that
aldosterone enhances
IGF-I signaling and biological actions in VSMCs through induction of OPN followed by its subsequent activation of the αVβ3-integrin and by increasing
IGF-I receptor. These changes are mediated in part through increased oxidative stress. The findings suggest a new mechanism by which
aldosterone could accelerate the development of
atherosclerosis.